Ethris announces research based alliance on SNIM modified RNA with Shire
Ethris GmbH and Shire announce the initiation of a research based alliance focused on the development and commercialization of novel RNA-based therapeutics.
Many devastating human diseases are the result of an inability of the body’s cells to make specific proteins that have an essential function for the whole body. The replacement of proteins with normally functioning ones provides a potential approach to treat multiple devastating diseases. Ribonucleic acids (RNAs) that encode for such proteins have been the focus of much biopharmaceutical research and development, however, RNA’s inherent instability and immunogenicity has proven to be a significant hurdle in the past.
Ethris and its co-founders – Dr. Carsten Rudolph and Prof. Christian Plank, have developed a novel RNA modification technology that creates Stable and Non-Immunogenic Messenger RNA (SNIM®-RNA) molecules that are suited for use in protein replacement therapies to treat monogenic genetic diseases.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.